Literature DB >> 8426624

Hodgkin's disease.

V T DeVita1, S M Hubbard.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8426624     DOI： 10.1056/NEJM199302253280808

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Radiographic enlargement of mandibular canal as first feature of non-Hodgkin's lymphoma.

Authors:  N Buric; G Jovanovic; Z Radovanovic; M Buric; M Tijanic
Journal:  Dentomaxillofac Radiol       Date:  2010-09       Impact factor: 2.419

2.  90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Authors:  John E Janik; John C Morris; Deirdre O'Mahony; Stefania Pittaluga; Elaine S Jaffe; Christophe E Redon; William M Bonner; Martin W Brechbiel; Chang H Paik; Millie Whatley; Clara Chen; Jae-Ho Lee; Thomas A Fleisher; Maggie Brown; Jeffrey D White; Donn M Stewart; Suzanne Fioravanti; Cathryn C Lee; Carolyn K Goldman; Bonita R Bryant; Richard P Junghans; Jorge A Carrasquillo; Tat'Yana Worthy; Erin Corcoran; Kevin C Conlon; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

3.  90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma.

Authors:  Kevin C Conlon; Claude Sportes; Martin W Brechbiel; Daniel H Fowler; Ronald Gress; Milos D Miljkovic; Clara C Chen; Millie A Whatley; Bonita R Bryant; Erin M Corcoran; Karen A Kurdziel; Stefania Pittaluga; Chang H Paik; Jae Ho Lee; Thomas A Fleisher; Jorge A Carrasquillo; Thomas A Waldmann
Journal:  Cancer Biother Radiopharm       Date:  2020-04-09       Impact factor: 3.099

Review 4.  First-line treatment of Hodgkin's lymphoma.

Authors:  Beate Klimm; Andreas Engert; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

5.  Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.

Authors:  O Sezer; J Eucker; C Jakob; O Kaufmann; P Schmid; K Possinger
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

6.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

Review 7.  Multiple primary enoral soft tissue manifestations of a Hodgkin lymphoma--case report and literature review.

Authors:  P W Kämmerer; E Schiegnitz; T Hansen; G F Draenert; H D Kuffner; M O Klein
Journal:  Oral Maxillofac Surg       Date:  2012-04-18

8.  The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood.

Authors:  A Claviez; M Tiemann; J Peters; H Kreipe; R Schneppenheim; R Parwaresch
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

9.  Mediastinal tumors in children: experience with 196 cases.

Authors:  J L Grosfeld; M A Skinner; F J Rescorla; K W West; L R Scherer
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

10.  Disparities in survival after Hodgkin lymphoma: a population-based study.

Authors:  Theresa H M Keegan; Christina A Clarke; Ellen T Chang; Sarah J Shema; Sally L Glaser
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.